Scholars Central

Conference abstractPublished 13 Jun 2016

Development of a novel polyherbal topical formulation for the management of eczema

Authors: Anu T Singh, Nadav Shraibom, Alka Madaan, Ritu Verma, Anika Chaudhary, Gautam Mishra, Pratibha Singh, Ronodip Kar, Sheetal Dobhal, Manu Jaggi

Sirbal Limited, Cyprus; Dabur Research Foundation, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Eczema is an inflammatory, chronically relapsing, non-contagious and a pruritic disease with itchy, red, swollen and cracked skin. Current management strategies include oral medications, steroid creams and light therapy. We have developed a novel aqueous mixture (SIRB-001) consisting of 3 Traditional Chinese Medicine (TCM) based herbs; Rheum palmatum L. (Da Huang), Rehmannia glutinosa Libosch (Sheng di huang) and Lonicera Japonica (Jin yin hua) in the ratio 1:1:3. SIRB-001 has previously demonstrated promising anti-psoriatic activity in pre-clinical and clinical studies. SIRB-001 was further tested for efficacy in eczema using preclinical models, followed by clinical trial. SIRB-001 has demonstrated significant inhibitory effects on secretion of TNF-Ã?±, TARC and VEGF in keratinocytes (HaCaT). Considerable down-regulation of IL-6 in RAW264.7 cells and IgE in human myeloma cell line-U-266 was observed. SIRB-001 also exhibited inhibition of JAK-1/JAK-3. SIRB-001 based cream was developed and was found to be highly safe in animal studies. Encouraging preclinical results paved the path for clinical investigation in 30 subjects with eczematous lesions. The efficacy, safety and tolerance of SIRB-001 cream was evaluated in a mono-centric, open label study with treatment regimen of twice daily application for 4 weeks. At weekly intervals, Eczema Severity Index (ESI) and Investigator's Global Assessment Severity (IGAS) was determined in subjects. SIRB-001 cream demonstrated significant (p<0.001) decrease in ESI, IGAS (d28-d0) and was well tolerated in human patients with a good safety profile. Hence, it can be concluded that SIRB-001 is a highly effective new treatment with a favorable safety profile for management of eczema.

Subjects

Dermatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Dermatology Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Dermatology Research
  • SubjectDermatology
  • BylineArticles whose byline prints “Anu T Singh”
  • BylineArticles whose byline prints “Nadav Shraibom”
  • BylineArticles whose byline prints “Alka Madaan”
  • BylineArticles whose byline prints “Ritu Verma”
  • BylineArticles whose byline prints “Anika Chaudhary”
  • BylineArticles whose byline prints “Gautam Mishra”
  • BylineArticles whose byline prints “Pratibha Singh”
  • BylineArticles whose byline prints “Ronodip Kar”